Data Updates:
$GMDA (-13.3%) – Topline phase 3 results & BLA plans
$CYTK (+22.8%) – Phase 2 interim analysis – proceed to cohort 2
$ATNX (-3.3%) – Updated phase 3 data for oraxol
$EDIT (+17%) – Submitted IND for EDIT-301 in SCD
$FPRX (-12.5%) – Will present phase 2 data at ASCO 01/15/21
$GTHX (-7.5%) – Phase 2 data for Triliciclib and phase 1 update
Financial:
$KURA (-1.2%) – Priced their offering at $37/share
$SNDX (+7%) – Priced their offering at $23/share
$MIRM (+0.67%) - $210 million funding arrangement – tiered revenue-based
Comments